Donor Leukocyte Infusions (DLI) in the Treatment of AML Patients Relapsed After Allogeneic Bone Marrow Transplantation

Savchenko Vg(National Research Center for Hematology Russian Academy of Medical Sciences), Michail M. Petrov(National Medical Research Center for Hematology), Л. П. Менделеева(National Research Center for Hematology Russian Academy of Medical Sciences), H. Parovitchnikova(National Medical Research Center for Hematology), L. S. Lubimova(National Medical Research Center for Hematology), L. P. Poreshina(National Medical Research Center for Hematology), H. Gribanova(National Medical Research Center for Hematology)
Hämatologie und Bluttransfusion
January 1, 1996
10.1007/978-3-642-78907-6_64
Cited by 0

Related Papers

Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation
|Bone Marrow Transplantation|2014|195
Atlas of RNA sequencing profiles for normal human tissues
|Scientific Data|2019|142
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
|The Oncologist|2010|92
Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma
|Leukemia & lymphoma/Leukemia and lymphoma|2015|59
Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of proteasome inhibitors in multiple myeloma cells
|Leukemia|2015|53